| 1121/1816 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 1122/1816 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 1123/1816 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |
| 1124/1816 | US=67 / Biol/Mol Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin analogue therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 585-637. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. TERAPIA ANALOGA DA SOMATOSTATINA; ACROMEGALIA; CARCINOIDE; SINDROME CARCINOIDE; HORMONIO DE CRESCIMENTO; LUTECIO; OCTREOTIDE; NEUROENDOCRINO; PROLIFERACAO; CINTILOGRAFIA; RECEPTOR DE SOMATOSTATINA; SOMATULINA; TUMOR; ITRIO |
| 1125/1816 | US=67 / Biol/Mol Dy GK, Adjei AA. Patient selection for rational development of novel anticancer agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 641-8. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. AGENTES ANTICANCERIGENOS; SELECAO DOS PACIENTES; TERAPIA-ALVO; BIOMARCADORES; EXPRESSAO GENICA; AMPLIFICACAO GENICA |
| 1126/1816 | US=67 / Biol/Mol Dubey S, Schiller JH. Clinical trial design with targeted agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 649-55. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ESTUDO CLINICO; AGENTES DIRECIONADOS; ENSAIOS CLINICOS; AGENTES ALVOS |
| 1127/1816 | US=67 / Biol/Mol Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO |
| 1128/1816 | US=67 / Biol/Mol Shankar LK, Menkens A, Sullivan DC. Molecular imaging in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 675-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; IMAGEM MOLECULAR; BIOMARCADORES DE IMAGEM; BIOMARCADORES IN VIVO; TESTES DE CANCER; PROCESSO NEOPLASICO; AGENTES PET; CONTRASTE AGENTES MR; TECNOLOGIA OPTICA |
| 1129/1816 | US=67 / Biol/Mol Chen HX, Dancey JE. Combinations of molecular-targeted therapies: opportunities and challenges. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 693-705. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 1130/1816 | US=67 / Biol/Mol Tomaszewski JE, Doroshow JH. Preclinical development of molecularly targeted agents in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; DESENVOLVIMENTO PRE-CLINICO; AGENTES ALVO MOLECULARES; AGENTES ANTITUMORAIS; DESENVOLVIMENTO DE DROGAS; ALVOS MOLECULARES; FARMACOCINETICA; FARMACODINAMICA; TOXICOLOGIA |
| 1131/1816 | US=69 / Câncer Wheler J, Kurzrock R. Perspectives: bench to bedside and back. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 1-19. ISBN 978-1-60327-423-4. TERAPIA DE CANCER DIRECIONADA; MEDICINA TRANSLACIONAL; BIOINFORMATICA; ACIDO TRANS-RETINOICO; GIST; IMATINIB; DASATINIBE; EPIGENETICA; DECITABINA; DETER HIPOTESE CELULAR |
| 1132/1816 | US=69 / Câncer Estey E. Targeted therapy in acute myelogenous leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 21-42. ISBN 978-1-60327-423-4. TERAPIA DE CANCER DIRECIONADA; TERAPIA-ALVO NA LEUCEMIA MIELOIDE AGUDA; LEUCEMIA MIELOIDE AGUDA; ATRA E ARSENICO TRIOXIDO OZOGAMICINA; FLT-3 INIBIDORES; INIBIDORES DA FARNESIL TRANSFERASE; EPIGENETICA AGENTES DE ACAO |
| 1133/1816 | US=69 / Câncer Craft BS, Moulder S. Targeted therapy in breast cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 43-59. ISBN 978-1-60327-423-4. TERAPIA-ALVO NO CANCRO DA MAMA; CANCER DE MAMA; TERAPIA BIOLOGICA; TERAPIA-ALVO; TERAPIA ADJUVANTE; DOENCA METASTATICA |
| 1134/1816 | US=69 / Câncer Tsimberidou AM, Keating MJ. Targeted therapy in chronic lymphocytic leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 61-86. ISBN 978-1-60327-423-4. TERAPIA-ALVO EM LEUCEMIA LINFOCITICA CRONICA; CLL; PROGNOSTICO; TERAPIA; ALVO; FASE I; FLUDARABINA; ALEMTUZUMAB; RITUXIMAB; LENALIDOMIDA; TERAPIA GENETICA |
| 1135/1816 | US=69 / Câncer Jabbour E, Cortes J, Kantarjian H. Targeted therapy in chronic myeloid leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 87-99. ISBN 978-1-60327-423-4. TERAPIA-ALVO NA LEUCEMIA MIELOIDE CRONICA; LEUCEMIA MIELOIDE CRONICA; INIBIDOR DA TIROSINA QUINASE; RESISTENCIA; BCR-ABL |
| 1136/1816 | US=69 / Câncer Kopetz S. Targeted therapy in colorectal cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 101-23. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CANCER COLORRETAL; EGFR; VEGF; ANTICORPOS MONOCLONAIS |
| 1137/1816 | US=69 / Câncer Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 125-56. ISBN 978-1-60327-423-4. TERAPIA-ALVO; NAO-PEQUENAS DE CANCER DE PULMAO DE CELULAS; EGFR; ERLOTINIB; GEFITINIB; VEGFR |
| 1138/1816 | US=69 / Câncer Wedgwood A, Younes A. Targeted therapy in lymphoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 157-82. ISBN 978-1-60327-423-4. TERAPIA-ALVO NO LINFOMA; ANTICORPO; LINFOMA; ANTIGENO; RECEPTOR; INIBIDOR; QUINASE |
| 1139/1816 | US=69 / Câncer Davies M, Patel S, Kim KB. Targeted therapy in melanoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 183-211. ISBN 978-1-60327-423-4. TERAPIA-ALVO EM PACIENTES COM MELANOMA; MELANOMA; TRANSDUCAO DE SINAL; QUINASE DO RECEPTOR; B-RAF; N-RAS; PTEN; MAP QUINASE; NFKB; ANTIOGENESIS; IMMUNOTARGETING |
| 1140/1816 | US=69 / Câncer Zhou Y, Alexanian R, Wang M. Targeted therapy in multiple myeloma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 213-36. ISBN 978-1-60327-423-4. TERAPIA-ALVO; MIELOMA MULTIPLO; PATOGENESE MOLECULAR; MICROAMBIENTE |